Published in Br J Urol on November 01, 1998
Lymphoepithelioma-like carcinoma of the bladder: three cases with clinicopathological and p53 protein expression study. Virchows Arch (2004) 1.24
Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer (2004) 1.20
Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am J Pathol (2000) 1.10
Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer (2001) 0.94
p53 and p53-regulated genes in bladder cancer. BJU Int (1999) 0.75
Vitamin C exhibits pro-oxidant properties. Nature (1998) 3.22
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol (2000) 2.73
Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci (2001) 2.64
Renal impairment associated with non-steroidal anti-inflammatory drugs. Ann Rheum Dis (1987) 2.48
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer (2011) 2.28
Screening for prostate cancer in the UK. Seems to be creeping in by the back door. BMJ (2001) 2.22
Hypoxic-reperfusion injury in the inflamed human joint. Lancet (1989) 2.11
P53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys (1996) 2.06
Ambulatory urodynamics. Br J Urol (1996) 2.06
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta (2002) 1.98
Quality assessment of genetic markers used for therapy stratification. J Clin Oncol (2003) 1.92
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res (1997) 1.91
Free-radical oxidation (peroxidation) products in serum and synovial fluid in rheumatoid arthritis. J Rheumatol (1981) 1.86
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene (2003) 1.83
Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer (2010) 1.79
The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol (1998) 1.76
Mechanism of exacerbation of rheumatoid synovitis by total-dose iron-dextran infusion: in-vivo demonstration of iron-promoted oxidant stress. Lancet (1987) 1.69
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med (1996) 1.68
Tip60 is a nuclear hormone receptor coactivator. J Biol Chem (1999) 1.67
Written consent about sexual function in men undergoing transurethral prostatectomy. Br J Urol (1994) 1.65
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer (2011) 1.62
Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate (1998) 1.61
Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res (2001) 1.52
Self-perpetuating mechanisms of immunoglobulin G aggregation in rheumatoid inflammation. J Clin Invest (1985) 1.51
Bladder function in healthy volunteers: ambulatory monitoring and conventional urodynamic studies. Br J Urol (1994) 1.51
Clinical outcome and quality of life following enterocystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction. Br J Urol (1995) 1.50
Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol (1995) 1.49
Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet (1987) 1.48
Screening for bacteriuria in urological patients using reagent strips. Br J Urol (1992) 1.48
Is chronic synovitis an example of reperfusion injury? Ann Rheum Dis (1986) 1.45
Mucin gene expression in human urothelium and in intestinal segments transposed into the urinary tract. J Urol (2000) 1.45
Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer (2001) 1.43
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med (2016) 1.41
Effect of intravenous iron dextran on rheumatoid synovitis. Ann Rheum Dis (1985) 1.41
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
The effect of prostatectomy on symptom severity and quality of life. Br J Urol (1996) 1.39
Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Mol Endocrinol (2000) 1.38
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer (2001) 1.37
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer (2009) 1.36
Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression. Oncogene (2009) 1.33
Rectal, bladder and sexual function after mucosal proctectomy with and without a pelvic reservoir for colitis and polyposis. Br J Surg (1982) 1.33
C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol (1996) 1.30
Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer (1987) 1.30
A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study. J Urol (2000) 1.27
Cerebral and ocular toxicity induced by desferrioxamine. Q J Med (1985) 1.21
Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology. BJU Int (2000) 1.21
FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene (1999) 1.21
Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer (2006) 1.19
UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer (2009) 1.18
Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology (1992) 1.18
Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol (1999) 1.17
Free radicals and antioxidant systems in health and disease. Br J Hosp Med (1990) 1.14
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol (2004) 1.14
Transurethral prostatic resection or laser therapy for men with acute urinary retention: the ClasP randomized trial. J Urol (2001) 1.12
Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br J Cancer (2010) 1.12
Fluorescent lipid-peroxidation products in synovial fluid. Clin Sci (Lond) (1979) 1.11
The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res (2001) 1.11
Urinary 8-oxo-2'-deoxyguanosine--source, significance and supplements. Free Radic Res (2000) 1.11
The behaviour of caeruloplasmin in stored human extracellular fluids in relation to ferroxidase II activity, lipid peroxidation and phenanthroline-detectable copper. Biochem J (1985) 1.11
p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol (2001) 1.10
Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer (2001) 1.10
Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev (2003) 1.08
Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability. J Urol (1996) 1.08
Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group. Med Pediatr Oncol (2001) 1.08
Tip60 is a co-activator specific for class I nuclear hormone receptors. J Biol Chem (2001) 1.07
Free radicals in biological systems--a review orientated to inflammatory processes. Br Med Bull (1987) 1.07
A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability. J Urol (2001) 1.07
Free radical oxidation (peroxidation)products in plasma in normal and abnormal pregnancy. Ann Clin Biochem (1981) 1.07
The National Prostatectomy Audit: the clinical management of patients during hospital admission. Br J Urol (1995) 1.07
p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol (1992) 1.06
Immunohistochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues. J Pathol (1991) 1.05
P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol (1992) 1.05
Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology (2004) 1.05
Increased diene conjugates in diabetic subjects with microangiopathy. Diabet Med (1987) 1.04
Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res (1989) 1.04
bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer (1996) 1.03
Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technol Assess (2012) 1.03
Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer (1996) 1.03
Surface localization of sacral foramina for neuromodulation of bladder function. An anatomical study. Eur Urol (1996) 1.02
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene (2011) 1.02
The effects of vitamin C supplementation on protein oxidation in healthy volunteers. Biochem Biophys Res Commun (2000) 1.02
The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol (1997) 1.02
Molecular and cellular effects of ultraviolet light-induced genotoxicity. Crit Rev Clin Lab Sci (1998) 1.02
Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res (2000) 1.02
The human red blood cell glyoxalase system in diabetes mellitus. Diabetes Res Clin Pract (1989) 1.01
Long-term monitoring of bladder pressure in chronic retention of urine: the relationship between detrusor activity and upper tract dilatation. J Urol (1988) 1.01
Histological profile of tumours from MYCN transgenic mice. J Clin Pathol (2008) 1.01
Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res (1997) 1.01
Deaths and complications following prostatectomy in 1400 men in the northern region of England. Northern Regional Prostate Audit Group. Br J Urol (1994) 1.01
The role of the tumour suppressor p33 ING1b in human neoplasia. J Clin Pathol (2003) 1.01
Chronic retention of urine. The relationship between upper tract dilatation and bladder pressure. Br J Urol (1986) 1.00
Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer (2003) 1.00
Disturbed handling of ascorbic acid in diabetic patients with and without microangiopathy during high dose ascorbate supplementation. Diabetologia (1991) 1.00
Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res (1998) 0.99